Latest International Markets News

Apiam Animal Health posted modest FY25 revenue growth but saw net profit plunge due to asset impairments, while receiving a non-binding acquisition proposal from Adamantem Capital.

Sigma Healthcare reports a robust FY25 performance post-merger with Chemist Warehouse Group, delivering strong revenue growth and upgraded synergy targets. The company signals continued expansion and efficiency gains heading into FY26.

Sigma Healthcare has completed a reverse acquisition merger with Chemist Warehouse, reporting $6 billion in revenue and declaring a fully franked dividend. The merger reshapes Australia’s pharmacy landscape with ambitious synergy targets and operational shifts.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Chrysos Corporation reported a robust 46% revenue increase to A$66.1 million for FY25 but faced a significant net loss of A$8.2 million, reflecting rising costs and operational challenges.

SPC Global reports stronger-than-expected FY25 results driven by international growth and synergy gains, while unveiling a new premium beverage division and a major lender transition.

SPC Global Holdings Ltd reported a 40.66% surge in gross revenue to $383 million for FY2025, driven by strategic acquisitions and operational growth. However, the group recorded a net loss of $41.1 million, reflecting restructuring and merger costs.

Felix Group Holdings Ltd has launched a capped $1 million Share Purchase Plan (SPP) offering eligible shareholders a discounted entry to support its strategic acquisition of Nexvia Pty Ltd and fuel growth initiatives. This retail-focused SPP complements a larger institutional placement as Felix aims to expand its enterprise software footprint.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.